Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation
NCT ID: NCT00219635
Last Updated: 2012-11-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
138 participants
INTERVENTIONAL
2005-01-31
2005-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
UK-390,957
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
San Bernardino, California, United States
Pfizer Investigational Site
Metairie, Louisiana, United States
Pfizer Investigational Site
Watertown, Massachusetts, United States
Pfizer Investigational Site
Kansas City, Missouri, United States
Pfizer Investigational Site
Washington, Missouri, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
Williamsville, New York, United States
Pfizer Investigational Site
Beachwood, Ohio, United States
Pfizer Investigational Site
Portland, Oregon, United States
Pfizer Investigational Site
Knoxville, Tennessee, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, United States
Pfizer Investigational Site
St Leonards, New South Wales, Australia
Pfizer Investigational Site
Malvern, Victoria, Australia
Pfizer Investigational Site
Victoria, British Columbia, Canada
Pfizer Investigational Site
Barrie, Ontario, Canada
Pfizer Investigational Site
London, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Nr Lichfield, Staffordshire, United Kingdom
Pfizer Investigational Site
Devon, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A3871029
Identifier Type: -
Identifier Source: org_study_id